| Name | Title | Contact Details |
|---|
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.
Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
We are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. We are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.